Cargando…
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection
Background: Essential tremor (ET) is a common, progressive neurological syndrome with bilateral upper-limb dysfunction of at least 3-year duration, with or without tremor in other body locations. This disorder has a negative impact on daily function and quality of life. A single oral therapy has bee...
Autores principales: | Papapetropoulos, Spyros, Lee, Margaret S., Boyer, Stacey, Newbold, Evan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579833/ https://www.ncbi.nlm.nih.gov/pubmed/31244760 http://dx.doi.org/10.3389/fneur.2019.00597 |
Ejemplares similares
-
A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor
por: Papapetropoulos, Spyros, et al.
Publicado: (2021) -
Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description
por: Waliszewski, Matthias, et al.
Publicado: (2020) -
Calm and smart? A selective review of meditation effects on decision making
por: Sun, Sai, et al.
Publicado: (2015) -
Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models
por: Meregalli, Cristina, et al.
Publicado: (2021) -
The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
por: Thorlund, Kristian, et al.
Publicado: (2023)